Telaprevir for HIV/Hepatitis C Virus–Coinfected Patients Failing Treatment With Pegylated Interferon/Ribavirin (ANRS HC26 TelapreVIH): An Open-Label, Single-Arm, Phase 2 Trial
Clicks: 145
ID: 273793
2014
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
0.6
/100
2 views
2 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Retreatment with telaprevir, pegylated interferon, and ribavirin resulted in an 80% sustained virological response rate in HIV/hepatitis C virus–coinfected pati| Reference Key |
laurent2014clinicaltelaprevir
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Cotte, Laurent;Braun, Joséphine;Lascoux-Combe, Caroline;Vincent, Corine;Valantin, Marc-Antoine;Sogni, Philippe;Lacombe, Karine;Neau, Didier;Aumaitre, Hugues;Batisse, Dominique;de Truchis, Pierre;Gervais, Anne;Michelet, Christian;Morlat, Philippe;Vittecoq, Daniel;Rosa, Isabelle;Bertucci, Inga;Chevaliez, Stéphane;Aboulker, Jean-Pierre;Molina, Jean-Michel;for the French National Agency for Research on AIDS and Viral Hepatitis (ANRS) HC26 Study Group; |
| Journal | clinical infectious diseases |
| Year | 2014 |
| DOI | DOI not found |
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.